VSTM · Verastem, Inc.
$6.23
+0.15 (+2.47%)
At close · Jul 28
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In accordance with the applicable accounting standards, these conditions raise substantial doubt about the Company's ability to continue as a going concern for twelve months after the date the condensed consolidated financial statements are issued.”View the 10-Q filed May 7, 2026
Market Cap
$534.27M
Shares
87.87M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$30.91M
+209.1%
FY2025
Net Income
-$209.47M
-60.3%
FY2025
Gross Margin
99.38%
FY2018
Operating Margin
-550.33%
+599.2pp
FY2025
Diluted EPS
-$3.02
+17.5%
FY2025
Operating Cash Flow
-$137.51M
-31.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $30.91M | $10M | $2.6M | $2.6M | $2.05M | $88.52M | $17.46M | $26.72M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $165K | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $26.55M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | 99.38% | — | — | — | — | — | — | |
| $123.67M | $114.6M | $81.33M | $61.36M | $50.56M | $39.35M | $41.38M | $45.78M | $43.65M | $46.42M | $19.78M | $40.57M | $35.45M | $57.93M | $32M | |
| — | — | — | — | — | — | — | — | — | $21.38M | $17.22M | $17.63M | $18.16M | $30.19M | $14.72M | |
| $88.42M | $81.15M | $43.62M | $30.73M | $24.98M | $24.12M | $62.76M | $101.21M | $77.27M | — | — | — | — | — | — | |
| — | $698K | — | — | $793K | $793K | $793K | $1.57M | $423K | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | $670K | $754K | $427K | $526K | $290K | |
| — | — | — | — | — | $0 | $4.78M | — | — | — | — | — | — | — | — | |
| $137.08M | — | — | — | — | — | — | — | $121.5M | $67.8M | $37M | $58.2M | $53.61M | $88.11M | $46.71M | |
| $220.44M | $201.04M | $124.96M | $92.08M | $75.53M | $63.46M | $137.88M | $149.8M | — | — | — | — | — | — | — | |
| -$170.85M | -$170.13M | -$114.96M | -$92.08M | -$72.94M | -$61.41M | -$49.36M | -$132.34M | -$94.78M | -$67.8M | -$37M | -$58.2M | -$53.61M | -$88.11M | -$46.71M | |
| — | -550.33% | -1149.56% | -3547.15% | -2809.59% | -2991.18% | -55.76% | -758.14% | -354.75% | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | -$36.33M | -$57.45M | -$53.18M | -$87.59M | -$46.42M | |
| $1.33M | $1.14M | $4.56M | $4.14M | $2.14M | $9.97M | $15.79M | $20.61M | $5.81M | $559K | — | — | — | — | — | |
| $4.41M | $4.07M | $4.15M | $6.21M | $1.22M | $181K | $515K | $4.38M | $2.6M | $561K | $562K | $334K | $242K | $461K | $261K | |
| -$224K | -$203K | -$123K | -$109K | $47K | -$1.31M | -$1.31M | -$641K | — | — | — | — | — | — | — | |
| — | -$209.47M | -$130.45M | — | -$73.81M | -$71.2M | -$67.53M | — | — | — | — | — | — | — | — | |
| — | $185K | $185K | — | $0 | $0 | $194K | — | — | — | — | — | — | — | — | |
| -$193.96M | -$209.47M | -$130.64M | -$87.37M | -$73.81M | -$71.2M | -$67.73M | -$149.21M | -$72.43M | -$67.8M | — | -$57.87M | -$53.37M | -$87.65M | -$46.45M | |
| — | -677.59% | -1306.37% | -3365.45% | -2843.3% | -3468.1% | -76.51% | -854.77% | -271.11% | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | -$36.44M | — | -$53.37M | -$87.69M | -$46.49M | |
| -$191.98M | -$204.24M | -$130.65M | -$87.35M | -$73.85M | -$71.22M | -$67.69M | -$149.32M | -$72.31M | -$67.83M | -$36.45M | -$57.83M | -$53.38M | -$87.63M | -$46.43M | |
| USD/shares | — | -$3.02 | -$3.66 | -$3.96 | -$4.56 | -$4.92 | -$5.28 | -$24.00 | -$13.44 | — | — | — | — | — | — |
| USD/shares | — | -$3.02 | -$3.66 | -$3.93 | -$4.56 | -$4.92 | -$5.28 | -$24.00 | -$16.44 | — | — | — | — | — | — |
| shares | — | 69.31M | 35.71M | 22.05M | 16.14M | 14.53M | 12.78M | 6.21M | 5.41M | 3.2M | 3.08M | 2.99M | 2.15M | 1.06M | 712.25K |
| shares | — | 69.31M | 35.71M | 22.05M | 16.14K | 14.53M | 12.78M | 6.21M | 5.78M | 3.2M | 3.08M | 2.99M | 2.15M | 1.06M | 712.25K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.57×
EV/EBIT
—
Peer median 24.58×
P/E (TTM)
—
Peer median 7.68×
Peer medians compare against the 308 similar-size Biotechnology companies (of 522 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2022 |
|---|---|---|---|
| Research Developing and Commercialization Drugs Segment | $30,914,000 | $10,000,000 | $2,596,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|
| Product | $30,914,000 | — | — | — | $15,232,000 | $12,339,000 | $1,718,000 |
| License | — | — | — | — | $2,912,000 | $5,117,000 | $25,000,000 |
| Copiktra License and Related Assets | — | $10,000,000 | $2,596,000 | $1,447,000 | $70,000,000 | — | — |
| Transition Services Revenue | — | — | — | $606,000 | $372,000 | — | — |
Key facts
CIK
1526119
CUSIP
92337C203
13F (30d)
20 filings
20 filers
Visit website
Investor relations